KB-1849

Tozorakimab

60898

Background of Tozorakimab

Interleukin (IL)-33 is a broad-acting IL-1 family cytokine that is released from stressed or damaged barrier tissues, including the endothelium and epithelium, following external triggers such as trauma, allergen exposure or infection. Tozorakimab, a novel high affinity IL-33 antibody, is the first anti-IL-33 antibody reported to inhibit signalling through both the IL-33red-ST2 and IL-33ox-RAGE/EGFR signalling pathways. The mechanism of action of tozorakimab is therefore distinct from anti-ST2 therapeutics that only target IL-33red-ST2 signalling. Tozorakimab has a superior affinity and a similar fast association rate for IL-33red compared with sST2, the decoy receptor for IL-33.

Specifications

Catalog Number	KB-1849
Antibody Name	Tozorakimab
Isotype	Human IgG1,lambda
FC Muations	Wild Type
Target	IL33
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

England E, Rees DG, Scott IC, Carmen S, Chan DTY, Chaillan Huntington CE, Houslay KF, Erngren T, Penney M, Majithiya JB, Rapley L, Sims DA, Hollins C, Hinchy EC, Strain MD, Kemp BP, Corkill DJ, May RD, Vousden KA, Butler RJ, Mustelin T, Vaughan TJ, Lowe DC, Colley C, Cohen ES. Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Sci Rep. 2023 Jun 17;13(1):9825.